Last reviewed · How we verify
Naltrexone intramuscular suspension
Naltrexone is an opioid receptor antagonist that blocks the action of opioids at their receptor sites.
Naltrexone is an opioid receptor antagonist that blocks the action of opioids at their receptor sites. Used for Treatment of opioid dependence, Alcohol dependence.
At a glance
| Generic name | Naltrexone intramuscular suspension |
|---|---|
| Also known as | Long-acting naltrexone, Extended-release naltrexone, XR-NTX, Vivitrol |
| Sponsor | University of Oslo |
| Drug class | Opioid receptor antagonist |
| Target | Opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
By binding to opioid receptors, naltrexone prevents opioids from exerting their effects, which can help to reduce cravings and prevent relapse in individuals with opioid use disorder. This mechanism of action is thought to be responsible for the therapeutic effects of naltrexone in treating addiction.
Approved indications
- Treatment of opioid dependence
- Alcohol dependence
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
Key clinical trials
- Naltrexone in AUD Reward Drinkers (PHASE4)
- Biomarkers of Injectable Extended Release Naltrexone Treatment (PHASE4)
- Extended Release Naltrexone for Opioid-Dependent Youth (PHASE4)
- Alcohol Disorder hOsPital Treatment Trial (PHASE4)
- Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings (PHASE4)
- ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals (PHASE3)
- Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway (PHASE3)
- ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naltrexone intramuscular suspension CI brief — competitive landscape report
- Naltrexone intramuscular suspension updates RSS · CI watch RSS
- University of Oslo portfolio CI